Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs that lower blood sugar levels in people with Type 2 diabetes and promote weight loss when used with a healthy diet and exercise
The available evidence should remain bounded to those research contexts and should not be extended into claims of human or veterinary therapeutic use.
Dose discipline: Adhere strictly to conservative dosing protocols
The compact size and stable profile make handling and preparation manageable in organized programs
The median annual costs per patient for CVD, coronary artery disease, heart failure, and stroke were, 112%, 107%, 59%, and 322% respectively higher compared with those for T2D patients without CVD as reported by a Canadian research team
As for other popular GLP-1s, the FDA listed these ongoing shortages: Dulaglutide (Trulicity) injection remains in shortage Liraglutide (Saxenda) injection remains in shortage More information Theres more on GLP-1 meds at the Cleveland Clinic